| Year |
Citation |
Score |
| 2020 |
Ludwig DL, Bryan RA, Dawicki W, Geoghegan EM, Liang Q, Gokhale M, Reddy V, Garg R, Allen KJH, Berger MS, Dadachova E. Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.714 |
0.319 |
|
| 2020 |
Nath R, Chu B, Chen L, Sadeghi A, Senglaub T, Kaiser L, Saganich C, Zgaljardic M, Rutar F, Harling S, Liang Q, Hari P, Besien Kv, Al-Kadhimi Z, Schuster MW, ... Reddy V, et al. Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Ongoing Phase III Sierra Trial Experience at 6 Study Sites Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.687 |
0.367 |
|
| 2020 |
Gyurkocza B, Nath R, Stiff PJ, Agura E, Litzow MR, Tomlinson B, Choe H, Abhyankar S, Seropian SE, Chen GL, Hari P, Al-Kadhimi Z, Foran J, Orozco JJ, Besien Kv, ... ... Reddy V, et al. Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.575 |
0.446 |
|
| 2019 |
Tomlinson BK, Reddy V, Berger MS, Spross J, Lichtenstein R, Gyurkocza B. Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial. Journal of Clinical Oncology. 37: 7048-7048. DOI: 10.1200/Jco.2019.37.15_Suppl.7048 |
0.336 |
|
| 2019 |
Chu BP, Pandit-Taskar N, Gyurkocza B, Liang Q, Miodownik D, Reddy V, Berger MS, Dauer LT. Feasibility of Administering Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC Blood. 134: 5839-5839. DOI: 10.1182/Blood-2019-131230 |
0.313 |
|
| 2019 |
Nath R, Geoghegan EM, Ulrickson ML, Spross JA, Lichtenstein RH, Konerth S, Fisher DR, Liang Q, Ludwig D, Reddy V, Berger MS, Gyurkocza B. Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy Blood. 134: 1958-1958. DOI: 10.1182/Blood-2019-128838 |
0.306 |
|
| 2019 |
Ludwig D, Bryan R, Dawicki W, Geoghegan EM, Liang Q, Seth S, Gokhale M, Berger MS, Reddy V, Garg R, Allen K, Dadachova E. Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy Blood. 134: 5601-5601. DOI: 10.1182/Blood-2019-128678 |
0.329 |
|
| 2019 |
Gyurkocza B, Nath R, Stiff PJ, Agura E, Litzow M, Tomlinson B, Choe HK, Abhyankar S, Seropian S, Chen GL, Hari P, Al-Kadhimi ZS, Foran JM, Orozco J, Besien KV, ... ... Reddy V, et al. Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Blood. 134: 5642-5642. DOI: 10.1182/Blood-2019-122776 |
0.397 |
|
| 2019 |
Tomlinson BK, Reddy V, Berger MS, Spross J, Lichtenstein R, Gyurkocza B. Rapid Reduction of Peripheral Blasts in Older Patients with Refractory Acute Myeloid Leukemia (AML) Using Re-Induction with Single Agent Anti-CD45 Targeted Iodine (131I) Apamistamab [Iomab-B] Radioimmunotherapy in the Phase III SIERRA Trial Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.117 |
0.339 |
|
| 2019 |
Nath R, Reddy V, Kapur A, Gebregergish S, Gurskyte L, Kulakova M, Heeg B, Berger MS. Survival of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Patients Receiving Stem Cell Transplantation (SCT) Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.407 |
0.359 |
|
| 2019 |
Reddy V, Berger MS, Kapur A, Gebregergish S, Gurskyte L, Kulakova M, Heeg B, Shah J, Nath R. Burden of Hospitalization in Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia Biology of Blood and Marrow Transplantation. 25: 104-105. DOI: 10.1016/J.Bbmt.2018.12.376 |
0.46 |
|
| 2018 |
Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, ... ... Reddy V, et al. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. PMID 30076185 DOI: 10.3324/Haematol.2017.182550 |
0.323 |
|
| 2018 |
Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Chaffee KG, Furman RR, Hillmen P, Sharman J, Seymour JF, Chanan-Khan AA, Byrd JC, ... ... Reddy V, et al. Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy Blood. 132: 4394-4394. DOI: 10.1182/Blood-2018-99-112989 |
0.358 |
|
| 2018 |
Agura E, Gyurkocza B, Nath R, Litzow MR, Tomlinson BK, Abhyankar S, Seropian S, Stiff PJ, Choe HK, Kebriaei P, Foran JM, Chen G, Levy MY, Lazarus HM, Giralt S, ... ... Reddy V, et al. Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial Blood. 132: 1017-1017. DOI: 10.1182/Blood-2018-99-111914 |
0.42 |
|
| 2017 |
Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Huang J, Lin M, Byrd JC, Chanan-Khan AA, Furman RR, Hallek M, Hillmen P, Jones J, Sharman JP, Ferrante L, ... Reddy V, et al. A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care Blood. 130: 4303-4303. DOI: 10.1182/Blood.V130.Suppl_1.4303.4303 |
0.342 |
|
| 2015 |
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, ... ... Reddy V, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 266-74. PMID 25445023 DOI: 10.1016/J.Bbmt.2014.10.021 |
0.45 |
|
| 2015 |
Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, ... ... Reddy V, et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 151-8. PMID 25316109 DOI: 10.1016/j.bbmt.2014.10.006 |
0.335 |
|
| 2014 |
Fleischhauer K, Fernandez-Viña MA, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe LA, Ciceri F, Dehn J, Gajewski J, Hale GA, Heemskerk MB, Marino SR, McCarthy PL, Miklos D, Oudshoorn M, ... ... Reddy V, et al. Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1. Bone Marrow Transplantation. 49: 1176-83. PMID 24955785 DOI: 10.1038/Bmt.2014.122 |
0.365 |
|
| 2014 |
Pasquini MC, Le Rademacher J, Flowers C, Lill M, Costa LJ, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, ... Reddy V, et al. Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma Biology of Blood and Marrow Transplantation. 20: S162. DOI: 10.1016/J.Bbmt.2013.12.259 |
0.318 |
|
| 2014 |
Duncan C, Majhail NS, Brazauskas R, Wang Z, Cahn J, Kamble RT, Frangoul HA, Hayashi RJ, Hsu JW, Jacobsohn DA, Kasow KA, Khera N, Lazarus HM, Loren AW, Maziarz RT, ... ... Reddy V, et al. Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the Cibmtr Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.073 |
0.409 |
|
| 2013 |
Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, ... ... Reddy V, et al. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 122: 3651-8. PMID 23982174 DOI: 10.1182/Blood-2013-05-501510 |
0.371 |
|
| 2013 |
Dobbelstein C, Ahn KW, Haagenson M, Hale GA, van Rood JJ, Miklos D, Waller EK, Spellman SR, Fernandez-Vina M, Ganser A, Aljurf M, Bornhaeuser M, Gupta V, Marino SR, Pollack MS, ... Reddy V, et al. Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 741-5. PMID 23380341 DOI: 10.1016/J.Bbmt.2013.01.020 |
0.471 |
|
| 2013 |
Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY, Dilley KJ, Frangoul HA, Gross TG, Hale GA, Hayashi RJ, Hijiya N, Kamble RT, Lazarus HM, Marks DI, ... Reddy V, et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplantation. 48: 363-8. PMID 22964594 DOI: 10.1038/Bmt.2012.166 |
0.346 |
|
| 2013 |
Khaled Y, Al-Hazzouri A, Mizrachi A, Reynolds R, Reddy V, Solh M. Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT. Bone Marrow Transplantation. 48: 310-1. PMID 22773127 DOI: 10.1038/Bmt.2012.135 |
0.346 |
|
| 2013 |
Flowers CR, Lill M, Costa LJ, Shore TB, Vaughan W, Craig M, Freytes CO, Shea TC, Horwitz ME, Fay JW, Mineishi S, Rondelli D, Mason J, Reddy V, Braunschweig I, et al. Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America Blood. 122: 768-768. DOI: 10.1182/Blood.V122.21.768.768 |
0.442 |
|
| 2012 |
Farnsworth P, Ward D, Reddy V. Persistent complete molecular remission after nilotinib and graft-versus-leukemia effect in an acute lymphoblastic leukemia patient with cytogenetic relapse after allogeneic stem cell transplantation. Experimental Hematology & Oncology. 1: 29. PMID 23210606 DOI: 10.1186/2162-3619-1-29 |
0.381 |
|
| 2012 |
Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, Chow R, Duncan C, Eldjerou LK, Gupta V, Hale GA, Halter J, Hayes-Lattin BM, Hsu JW, Jacobsohn DA, ... ... Reddy V, et al. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 1776-84. PMID 22863842 DOI: 10.1016/J.Bbmt.2012.06.018 |
0.423 |
|
| 2012 |
Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M, Frangoul H, Gupta V, Hale GA, Hurley CK, Marino S, Oudshoorn M, Reddy V, Shaw P, Lee SJ, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood. 120: 2918-24. PMID 22829628 DOI: 10.1182/Blood-2012-03-417758 |
0.453 |
|
| 2012 |
Pidala J, Wang T, Haagenson MD, Spellman S, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Vina M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, ... ... Reddy V, et al. Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes Blood. 120: 467-467. DOI: 10.1182/Blood.V120.21.467.467 |
0.438 |
|
| 2012 |
Khaled Y, Solh M, Lamontagne D, Batista A, Sullivan J, Chan-Fong S, Fondaw M, Reddy V. Successful Stem Cell Mobilization and Engraftment in Heavily Pretreated Multiple Myeloma Patients with Prior High Dose Melphalan and Autologous Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 18. DOI: 10.1016/J.Bbmt.2011.12.247 |
0.407 |
|
| 2011 |
Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 1775-82. PMID 21621629 DOI: 10.1016/J.Bbmt.2011.05.004 |
0.397 |
|
| 2011 |
Eksioglu EA, Kielbasa J, Eisen S, Reddy V. Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 13: 888-96. PMID 21609205 DOI: 10.3109/14653249.2011.579956 |
0.381 |
|
| 2011 |
Khaled Y, Beredo L, McEntee S, Fondaw M, Villegas M, Mountford K, Reddy V. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Community Cancer Centers: Single Institution Experience Biology of Blood and Marrow Transplantation. 17. DOI: 10.1016/J.Bbmt.2010.12.434 |
0.368 |
|
| 2010 |
Cable C, Buzzeo MP, Schold JD, Khan S, Leather H, Moreb J, Jamieson K, Scornik J, Amdur RJ, Wingard JR, Reddy V. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT Bone Marrow Transplantation. 45: 31-37. PMID 19543325 DOI: 10.1038/Bmt.2009.126 |
0.438 |
|
| 2010 |
Greinix HT, Besien Kv, Elmaagacli A, Hillen U, Knobler R, Parenti D, Reddy V, Michallet M, Flowers MED. Progressive Improvement In Steroid-Refractory/Dependent/Intolerant Cutaneous Chronic Graft-Versus-Host Disease (Cgvhd) Following A 24-Week Course Of Extracorporeal Photopheresis (Ecp) Biology of Blood and Marrow Transplantation. 16. DOI: 10.1016/J.Bbmt.2009.12.450 |
0.353 |
|
| 2008 |
Hahn T, McCarthy PL, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5728-34. PMID 18981462 DOI: 10.1200/Jco.2008.17.6545 |
0.426 |
|
| 2008 |
Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 93: 1852-8. PMID 18945751 DOI: 10.3324/Haematol.13033 |
0.492 |
|
| 2008 |
Buzzeo MP, Yang J, Casella G, Reddy V. A preliminary gene expression profile of acute graft-versus-host disease. Cell Transplantation. 17: 489-94. PMID 18714668 DOI: 10.3727/096368908785096042 |
0.454 |
|
| 2008 |
Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 112: 2667-74. PMID 18621929 DOI: 10.1182/Blood-2008-03-141481 |
0.385 |
|
| 2007 |
Buzzeo MP, Yang J, Casella G, Reddy V. Hematopoietic stem cell mobilization with G-CSF induces innate inflammation yet suppresses adaptive immune gene expression as revealed by microarray analysis. Experimental Hematology. 35: 1456-65. PMID 17761290 DOI: 10.1016/J.Exphem.2007.06.001 |
0.304 |
|
| 2007 |
Eksioglu EA, Mahmood SS, Chang M, Reddy V. GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Experimental Hematology. 35: 1163-71. PMID 17562355 DOI: 10.1016/J.Exphem.2007.05.001 |
0.342 |
|
| 2007 |
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England Journal of Medicine. 356: 335-47. PMID 17251530 DOI: 10.1056/Nejmoa061098 |
0.387 |
|
| 2007 |
Woan K, Reddy V. Potential therapeutic role of natural killer cells in cancer. Expert Opinion On Biological Therapy. 7: 17-29. PMID 17150016 DOI: 10.1517/14712598.7.1.17 |
0.319 |
|
| 2006 |
Reddy V, Levine JB, Mahmood SS, Schold JD, Meier-Kriesche H, Dunbar EM. Natural killer (NK) cells are associated with reduced relapse without increased graft-versus-host disease (GVHD) after allogeneic hematopoetic stem-cell transplantation (HSCT) Journal of Clinical Oncology. 24: 6542-6542. DOI: 10.1200/Jco.2006.24.18_Suppl.6542 |
0.446 |
|
| 2006 |
Flowers MED, Besien KV, Apperley J, Bacigalupo A, Elmaagacli A, Grigg A, Kolb H, Bouzas LF, Michallet M, Reddy V, Wang J, Williamson P, Knobler R, Greinix H. A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD. Blood. 108: 758-758. DOI: 10.1182/Blood.V108.11.758.758 |
0.337 |
|
| 2006 |
Miller KB, Chao NJ, Messner HA, Goldstein SC, Reddy V, Vaughan W, Devine S, Rowley SD, Waller N, Devetten M, Schiller GJ. A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis. Blood. 108: 5369-5369. DOI: 10.1182/Blood.V108.11.5369.5369 |
0.393 |
|
| 2006 |
Chandrasekar P, Azevedo WMd, Durrant S, Greinix H, Langston A, Lipton JH, Reddy V, Vesole DH, Tarantolo SR, Boparai N, Patino H, Ullmann AJ. 49 Development of invasive fingal infection and related mortality in hematopoietic stem cell transplant recipients with graft-versus-host disease receiving posaconazole versus fluconazole prophylaxis International Journal of Infectious Diseases. 10. DOI: 10.1016/S1201-9712(06)80047-0 |
0.428 |
|
| 2005 |
Reddy V, Winer AG, Eksioglu E, Meier-Kriesche HU, Schold JD, Wingard JR. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 1014-21. PMID 16338624 DOI: 10.1016/J.Bbmt.2005.08.032 |
0.383 |
|
| 2005 |
Seebach JD, Stussi G, Passweg JR, Loberiza FR, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 1006-13. PMID 16338623 DOI: 10.1016/J.Bbmt.2005.07.015 |
0.465 |
|
| 2005 |
Reddy V, Meier-Kriesche HU, Greene S, Schold JD, Wingard JR. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 11: 698-705. PMID 16125640 DOI: 10.1016/J.Bbmt.2005.05.013 |
0.404 |
|
| 2004 |
Reddy V, Iturraspe JA, Tzolas AC, Meier-Kriesche HU, Schold J, Wingard JR. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood. 103: 4330-4335. PMID 14962904 DOI: 10.1182/Blood-2003-09-3325 |
0.442 |
|
| 2004 |
Reddy V, Winer AG, Eksioglu E, Levine J, Meier-Kriesche H, Schold J, Mossak H, Wingard JR. High Levels of Interleukin-12 Are Associated with Reduced Incidence of Relapse and Death without Increasing Acute Graft-Versus-Host Disease (AGVHD) after Allogeneic Stem Cell Transplantation (SCT). Blood. 104: 295-295. DOI: 10.1182/Blood.V104.11.295.295 |
0.396 |
|
| 2004 |
Reddy V, Iturraspe JA, Tzolas AC, Meier-Kriesche H-, Schold J, Greene S, Wingard JR. Low circulating dendritic cell count after allogeneic stem cell transplantation (SCT) predicts death, relapse, and acute graft-versus-host disease (AGVHD) Biology of Blood and Marrow Transplantation. 10: 25. DOI: 10.1016/J.Bbmt.2003.12.104 |
0.445 |
|
| 2003 |
Cogle CR, Moreb JS, Leather HL, Finiewicz KJ, Khan SA, Reddy VS, Wingard JR. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. American Journal of Hematology. 73: 169-75. PMID 12827653 DOI: 10.1002/ajh.10342 |
0.382 |
|
| 2003 |
Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JH. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation. 31: 73-8. PMID 12621486 DOI: 10.1038/Sj.Bmt.1703790 |
0.437 |
|
| 2002 |
Mainwaring MG, Rimsza LM, Chen SF, Gomez SP, Weeks FW, Reddy V, Lynch J, May WS, Kahn S, Moreb J, Leather H, Braylan R, Rowe TC, Finiewicz KJ, Wingard JR. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels Leukemia and Lymphoma. 43: 989-999. PMID 12148910 DOI: 10.1080/10428190290021339 |
0.357 |
|
| 2002 |
Grow W, Moreb J, Roque D, Manion K, Leather H, Reddy V, Khan S, Finiewicz K, Nguyen H, Clancy C, Mehta P, Wingard J. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplantation. 29: 15-19. PMID 11840139 DOI: 10.1038/Sj.Bmt.1703332 |
0.454 |
|
| 2001 |
Khan SA, Gaa B, Pollock BH, Shea B, Reddy V, Wingard FR, Moreb JS. Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival Biology of Blood and Marrow Transplantation. 7: 433-438. PMID 11569888 DOI: 10.1016/S1083-8791(01)80010-0 |
0.454 |
|
| 2000 |
Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, Ferrara JLM. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation. 69: 691-693. PMID 10708136 DOI: 10.1097/00007890-200002270-00041 |
0.422 |
|
| 1999 |
Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy. Journal of Clinical Virology. 13: 149-159. PMID 10443791 DOI: 10.1016/S1386-6532(99)00029-3 |
0.46 |
|
| 1999 |
Reddy V, Khan S, Wingard JR. Treatment results in aplastic anemia trials need to be analyzed separately for pediatric and adult populations. Blood. 94: 1833-1834. DOI: 10.1182/Blood.V94.5.1833 |
0.31 |
|
| Show low-probability matches. |